Related Experiment Video
Updated: Jun 22, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
Pharmacogenetics in heart failure: promises and challenges.
Rudolf A de Boer1, Pim van der Harst, Dirk J van Veldhuisen
1University Medical Centre Groningen, Thoraxcentre, Department of Cardiology, P.O. Box 30.001, Groningen 9700RB, The Netherlands. r.a.de.boer@thorax.umcg.nl
Expert Opinion on Pharmacotherapy
|June 30, 2009
Summary
Genetic factors influence heart failure treatment response. Pharmacogenetics, the study of genetic variations in drug response, can personalize therapies like ACE-inhibitors and beta-blockers, improving patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Genetics
Background:
- Pharmacotherapy is central to heart failure management.
- Individual responses to heart failure medications vary significantly.
- Genetic factors are recognized as a key contributor to this variability.
Purpose of the Study:
- To review key pharmacogenetic targets in heart failure treatment.
- To explore the role of genetic polymorphisms in drug response.
- To advocate for advanced genetic screening methods.
Main Methods:
- Review of existing literature on pharmacogenetics and heart failure.
- Discussion of genetic polymorphisms affecting major neurohormonal inhibitors.
- Exploration of high-throughput genetic screening technologies.
Main Results:
- Genetic variations significantly modulate the effects of ACE-inhibitors and beta-blockers.
- Current clinical practice does not routinely incorporate genetic testing.
- Pharmacogenetic principles offer potential for personalized heart failure therapy.
Conclusions:
- Pharmacogenetics holds promise for tailoring heart failure treatments.
- Further large-scale prospective studies are needed to identify new therapeutic targets.
- Genetic screening can help define patient populations who will benefit most from specific drugs.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...